• 1. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 2. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 3. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Hydroquinolones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolones and derivatives Hydroquinolones

Recent Advances in the Study of 2,4-dimethyl-5,6,7,8-tetrahydroquinolin-5-one (CAS: 34192-19-3): A Comprehensive Research Brief

The compound 2,4-dimethyl-5,6,7,8-tetrahydroquinolin-5-one (CAS: 34192-19-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic scaffold, characterized by its unique structural features, has demonstrated promising potential in various therapeutic applications. Recent studies have focused on elucidating its pharmacological properties, synthetic pathways, and potential as a lead compound in drug discovery.

Structural analysis reveals that the tetrahydroquinolinone core of 34192-19-3 provides an excellent platform for molecular modifications, enabling researchers to explore structure-activity relationships (SAR) for targeted biological activities. The presence of both the keto group at position 5 and the methyl substituents at positions 2 and 4 creates distinct electronic and steric properties that influence its binding affinity to biological targets. Recent computational studies utilizing molecular docking simulations have identified potential binding pockets in various enzyme systems that may explain its observed bioactivity.

In synthetic chemistry, novel approaches to the preparation of 2,4-dimethyl-5,6,7,8-tetrahydroquinolin-5-one have been reported, with emphasis on green chemistry principles and atom economy. A 2023 study published in the Journal of Organic Chemistry described an efficient one-pot synthesis method using catalytic hydrogenation, achieving yields of up to 85% with excellent purity. These advancements in synthetic methodology have significantly improved the accessibility of this compound for further biological evaluation.

Pharmacological investigations have revealed multiple potential applications for 34192-19-3. Most notably, recent in vitro studies have demonstrated its inhibitory activity against several kinase targets implicated in inflammatory pathways. The compound showed selective inhibition of p38 MAP kinase with an IC50 of 2.3 μM, suggesting potential as an anti-inflammatory agent. Additionally, preliminary screening against a panel of cancer cell lines revealed moderate cytotoxic activity, particularly against breast cancer cell lines (MCF-7), warranting further structure optimization for improved potency.

The metabolic stability and pharmacokinetic profile of 2,4-dimethyl-5,6,7,8-tetrahydroquinolin-5-one have been investigated in recent preclinical studies. While the compound exhibits reasonable metabolic stability in human liver microsomes (t1/2 > 60 minutes), its moderate aqueous solubility (0.12 mg/mL at pH 7.4) presents formulation challenges that are currently being addressed through prodrug approaches and nanoparticle delivery systems. These findings highlight both the potential and limitations of this scaffold for therapeutic development.

Looking forward, the unique structural features and demonstrated biological activities of 34192-19-3 position it as a valuable scaffold for medicinal chemistry optimization. Current research directions include the development of analogs with improved target selectivity and pharmacokinetic properties, as well as exploration of its potential in combination therapies. The compound's versatility suggests it may find applications beyond its current investigated indications, possibly in neurological disorders or infectious diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)